Targeted therapy for HER-2: Personalized medicine for her, too

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 1, 2012, Pages 1-4

  Melichar, Bohuslav ^a   Plebani, Mario ^b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PACLITAXEL; PROGESTERONE RECEPTOR; RITUXIMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADULT; BONE METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; DRUG EFFICACY; DRUG INDICATION; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LOADING DRUG DOSE; LYMPH NODE METASTASIS; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; NEUROTOXICITY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE; BREAST TUMOR; DRUG DELIVERY SYSTEM; EDITORIAL; METABOLISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; RECEPTOR, ERBB-2;

EID: 84857817877     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.724     Document Type: Review

References (35)

1. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23. (Pubitemid 36842560)
2. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-8. (Pubitemid 37071889)
3. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9. (Pubitemid 36957839)
4. van de Vijver MJ, He YF, van't Veer LJ, Dai H, Hart AM, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009. (Pubitemid 35461656)
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-express HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
6. Piccart-Gebhart MJ, Procter M, Sci M, Leyland-Jones B, Goldhirsch A, Untch M, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72. (Pubitemid 41464705)
7. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. (Pubitemid 41464706)
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20. (Pubitemid 43290919)
9. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunopheno-type and gene amplification. J Clin Oncol 2001;19:2587-95. (Pubitemid 32441364)
10. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56. (Pubitemid 32366985)
11. Early Breast Cancer Trialists Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
12. Sivridis E, Stamos C, Fiska A, Nikolaos N, Koukourakis MI, Giatromanolaki A. c-erbB-2 and the "triple-state" in early breast carcinomas. Med Oncol 2010;27:578-84.
13. Melichar B, Plebani M. Laboratory medicine: an essential partner in the care of cancer patients. Clin Chem Lab Med 2011;49: 1575-8.
14. Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati G, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011;49:521-5.
15. Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med 2011;49:527-34.
16. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
17. Gown AM, Goldstein LC. The knowns and the unknowns in HER2 testing in breast cancer. Am J Clin Pathol 2011;136:5-6.
18. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32. (Pubitemid 34575634)
19. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259-67. (Pubitemid 43151545)
20. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.
21. Hornychová H, Melichar B, Tomšová M, Mergancová J, Urminská H, Ryška A. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 2008;26:1024-31.
22. Lauterlein JJ, Petersen ER, Olsen DA, Ostergaard B, Brandslund I. Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer. Clin Chem Lab Med 2011;49:877-83.
23. Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 2010;16:4226-35.
24. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43. (Pubitemid 46021510)
25. Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, et al. An open-label expanded access study of lapatinib and capeci-tabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010;21:474-80.
26. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:1-11.
27. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. (Pubitemid 351724903)
28. Sorensen PD, Madsen J, Brandslund I. Serum HER-2/ECD in monitoring breast cancer patients. Clin Chem Lab Med 2012;50: 175-6.
29. Tafe LJ, Tsongalis GJ. The human epidermal growth factor receptor 2 (HER2). Clin Chem Lab Med 2012;50:23-30.
30. Molina R, Escudero JM, Munoz M, Auge JM, Filella X. Circulating levels of HER-2/neu oncoprotein in breast cancer. Clin Chem Lab Med 2012;50:5-21.
31. Plebani M, Lippi G. HER2: closing the gap between laboratory testing and clinical practice. Am J Clin Pathol 2009;131:897-903.
32. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93:552-6. (Pubitemid 43079998)
33. Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F, et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 2011;459:1-10.
34. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asychronous paired metastases: impact on patient management. Oncologist 2008;13:838-44.
35. Sorensen PD, Jakobsen EH, Langkjer ST, Bokmand S, Ostergaard B, Olsen DA, et al. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin Chem Lab Med 2009;47:1117-23.